Microgels, methods for making microgels, and methods for using microgels
Drug-functionalized microgel particles with activated groups and neutral charge are produced efficiently, addressing production challenges and enabling cost-effective and rapid microgel manufacturing for cell interaction studies.
Patent Information
- Application Number
- JP2024534321
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-12-20
- Filing Date
- 2022-12-16
- Publication Date
- 2024-11-28
AI Technical Summary
Existing microgels face challenges in modification with functional groups and are time-consuming and expensive to produce.
The development of drug-functionalized microgel particles with neutral charge, activated functional groups, and specific dimensions, produced through a method involving polymerization, mechanical sieving, and quenching to achieve rapid and cost-effective production.
Enables efficient and quick production of microgel particles with precise drug loading, suitable for studying cell interactions and reducing production costs.
Smart Images

Figure 2024544237000001_ABST
Abstract
Description
[Technical field]
[0001] Claiming priority of related applications This application claims priority to a co-pending U.S. provisional application entitled “MICROGELS, METHODS OF MAKING MICROGELS AND METHODS OF USING MICROGELS” having Serial No.: 63 / 291,531, filed December 20, 2021, which is incorporated herein by reference in its entirety. [Background technology]
[0002] Although microgels are widely used, many have drawbacks with respect to modifying the microgels with functional groups. Also, microgels can be time consuming and expensive to produce. Thus, there is a need to have more options and to produce microgels using more efficient processes. Summary of the Invention
[0003] Aspects of the present disclosure provide microgels, microgel compositions, methods of making the microgels and microgel compositions, methods of using the microgels and microgel compositions, and the like.
[0004] The present disclosure provides a microgel composition comprising a plurality of drug-functionalized microgel particles having a neutral charge, the drug-functionalized microgel particles being made from a polymer, the polymer being quenched or functionalized with an activated functional group that is bonded to at least one type of drug via the activated functional group, the drug-functionalized microgel particles having a longest dimension of about 5-150 μm and an aspect ratio of about 1-1.5.
[0005] The present disclosure provides a microgel composition as described above and herein, wherein the activated functional group is an activated ester, an N-acylbenzotriazole group, an anhydride group, or an activated carbonate functional group, as well as a ketone / aldehyde for Schiff / imine chemistry, or a maleimide / acrylate for click chemistry.
[0006] The present disclosure provides a microgel composition as described above and herein, wherein the activated ester is selected from an N-hydroxysuccinimide (NHS) ester group, a sulfonated NHS ester group, a fluorophenyl ester group, a tosylate ester group, a mesylate ester group, or an O-acylisourea.
[0007] The present disclosure provides a microgel composition as described above and herein, wherein the activated carbonate functional group is succinimidyl carbonate.
[0008] The present disclosure provides a microgel composition as described above and herein, wherein the drug-functionalized microgel particles have an aspect ratio of about 1 to 1.5.
[0009] The present disclosure provides a microgel composition as described above and herein, wherein the drug-functionalized microgel particles have a random three-dimensional shape.
[0010] The present disclosure provides a microgel composition as described above and herein, wherein the polymer is selected from polyethylene glycol, polyacrylamide, polyacrylic acid, HEMA, and combinations thereof.
[0011] The present disclosure provides a microgel composition as described above and herein, wherein the polymer, prior to conjugation with at least one type of agent, has a concentration of activated ester groups of about 0.1-30 mol %.
[0012] The present disclosure provides microgel compositions as described above and herein, wherein greater than about 90-95% of the at least one drug is present on the surface of the drug-functionalized microgel particles.
[0013] The present disclosure provides a microgel composition as described above and herein, wherein the agent is a protein.
[0014] The present disclosure provides a microgel composition as described above and herein, wherein the protein is an antibody, an enzyme, or a cytokine.
[0015] The present disclosure provides a microgel composition as described above and herein, wherein the agent is a biomolecule containing an amine group.
[0016] The present disclosure provides a microgel composition as described above and herein, wherein the drug-functionalized microgel particles comprise about 2-10 different types of drugs.
[0017] The present disclosure provides a method of making a composition of drug-functionalized microgel particles as described above and herein, comprising: forming a uniform distribution of microgel particles, where the polymeric microgel particles have activated functional groups; separating the uniform distribution of microgel particles using a centrifugation process to obtain a set of microgel particles, where the set of microgel particles have a longest dimension of about 5-150 μm and an aspect ratio of about 1-1.5; binding a drug to a first amount of the activated functional groups of the polymer of the set of microgel particles, where a second amount of the activated functional groups are not bound to the drug; and quenching the second amount of the set of drug functional groups with amine groups to form drug-functionalized microgel particles.
[0018] The present disclosure provides a method of making the drug-functionalized microgel particle composition described above and herein, wherein the forming, separating, combining, and quenching steps are carried out for a period of about 60 to 120 minutes.
[0019] The present disclosure provides methods of making the compositions of drug-functionalized microgel particles as described above and herein, wherein the drug-functionalized microgel particles have a neutral charge, the drug-functionalized microgel particles are made from a polymer, the polymer is quenched or functionalized with an activated functional group that binds to at least one type of drug via the activated functional group, and the drug-functionalized microgel particles have a longest dimension of about 5-150 μm and an aspect ratio of about 1-1.5.
[0020] The present disclosure provides methods of making compositions of drug-functionalized microgel particles as described above and herein, wherein the activated functional groups are activated esters, N-acylbenzotriazole groups, anhydride groups, or activated carbonate functional groups, as well as ketones / aldehydes for Schiff / imine chemistry, or maleimides / acrylates for click chemistry.
[0021] The present disclosure provides a method of making the composition of drug-functionalized microgel particles described above and herein, wherein the activated ester is selected from an N-hydroxysuccinimide (NHS) ester group, a sulfonated NHS ester group, a fluorophenyl ester group, a tosylate ester group, a mesylate ester group, or an O-acylisourea.
[0022] The present disclosure provides a method of making the composition of drug-functionalized microgel particles described above and herein, wherein the activated carbonate functional group is succinimidyl carbonate.
[0023] The present disclosure provides a method of making the compositions of drug-functionalized microgel particles described above and herein, wherein the drug-functionalized microgel particles have an aspect ratio of about 1 to 1.5.
[0024] The present disclosure provides methods of making the compositions of drug-functionalized microgel particles described above and herein, wherein the drug-functionalized microgel particles have a random three-dimensional shape.
[0025] The present disclosure provides a method of making the composition of drug-functionalized microgel particles described above and herein, wherein the polymer is selected from polyethylene glycol, polyacrylamide, polyacrylic acid, HEMA, and combinations thereof.
[0026] The present disclosure provides methods of making compositions of drug-functionalized microgel particles as described above and herein, wherein the polymer prior to conjugation with at least one type of drug has a concentration of activated ester groups of about 0.1-30 mol %.
[0027] The present disclosure provides methods of making compositions of drug-functionalized microgel particles as described above and herein, wherein greater than about 90-95% of the at least one drug is present on the surface of the drug-functionalized microgel particle.
[0028] The present disclosure provides methods of making the compositions of drug-functionalized microgel particles described above and herein, wherein the drug is a protein.
[0029] The present disclosure provides methods of making the compositions of drug-functionalized microgel particles described above and herein, wherein the protein is an antibody, an enzyme, or a cytokine.
[0030] The present disclosure provides methods of making compositions of drug-functionalized microgel particles as described above and herein, wherein the drug is a biomolecule that contains an amine group.
[0031] The present disclosure provides methods of making compositions of drug-functionalized microgel particles as described above and herein, wherein the drug-functionalized microgel particles comprise about 2-10 different types of drugs.
[0032] The present disclosure provides a method for preparing a microgel block comprising: disposing a microgel block on a first side of a mechanical sieve, the mechanical sieve having a sieve of a selective characteristic size, the mechanical sieve having a second side opposite the first side, the microgel block including a polymer having an activated functional group; applying a first load to the microgel block to extrude the microgel block through the mechanical sieve to form a first plurality of fragments of the microgel block on the second side of the mechanical sieve, a collection reservoir positioned adjacent the second side of the mechanical sieve to receive the fragments of the microgel block; and forming a uniform distribution of the microgel particles. repeating this process using a new reservoir until a uniform distribution of microgel particles is formed; isolating the uniform distribution of microgel particles using a centrifugation process to obtain a set of microgel particles, the set of microgel particles having a longest dimension of about 5-150 μm and an aspect ratio of about 1-1.5; binding a drug to a first amount of activated functional groups of the polymer of the set of microgel particles, wherein a second amount of the activated functional groups is not bound to the drug; and quenching the second amount of the drug functional groups with an amine group to form the drug-functionalized microgel particle composition.
[0033] The present disclosure provides a method of making a composition of drug-functionalized microgel particles as described above and herein, wherein the steps of positioning the microgel block, applying a load, positioning the first plurality of pieces, separating, combining, and quenching are carried out for a period of about 60 to 120 minutes.
[0034] The present disclosure provides a method of making the drug-functionalized microgel particle composition described above and herein, wherein the quenching comprises using about 1.1 to 10 equivalents of an amine.
[0035] The present disclosure provides a method of making the composition of drug-functionalized microgel particles described above and herein, wherein the amine is a primary amine.
[0036] The present disclosure provides a method of making a composition of drug-functionalized microgel particles as described above and herein, wherein the quenching comprises using a molar excess of an amine relative to the second amount of the set of drug functional groups.
[0037] The present disclosure provides a method of making the composition of drug-functionalized microgel particles described above and herein, wherein the load is a mechanical force.
[0038] The present disclosure provides a method of making the compositions of drug-functionalized microgel particles described above and herein, in which the mechanical force is applied via a sterile syringe.
[0039] The present disclosure provides a method of making the composition of drug-functionalized microgel particles described above and herein, wherein the mechanical sieve has a selective characteristic size sieve of about 10 to 85 micrometer mesh.
[0040] The present disclosure provides a method of making the composition of drug-functionalized microgel particles described above and herein, wherein the first load is a uniformly distributed normal load.
[0041] The present disclosure provides a microgel polymer comprising a polymer functionalized with a first concentration of unquenched activated functional groups.
[0042] The present disclosure provides a microgel polymer as described above and herein, wherein the activated functional group is an activated ester, an N-acylbenzotriazole group, an anhydride group, or an activated carbonate functional group, as well as a ketone / aldehyde for Schiff / imine chemistry, or a maleimide / acrylate for click chemistry.
[0043] The present disclosure provides a microgel polymer as described above and herein, wherein the activated ester is selected from an N-hydroxysuccinimide (NHS) ester group, a sulfonated NHS ester group, a fluorophenyl ester group, a tosylate ester group, a mesylate ester group, or an O-acylisourea.
[0044] The present disclosure provides a microgel polymer as described above and herein, wherein the activated carbonate functional group is succinimidyl carbonate.
[0045] The present disclosure provides a microgel polymer as described above and herein, wherein the first concentration of activated functional groups is about 0.1-30 mol %, or about 5-30 mol %.
[0046] Many aspects of the present disclosure can be better understood with reference to the following drawings. The components in the drawings are not necessarily to scale, emphasis instead being placed upon clearly illustrating the principles of the present disclosure. Moreover, in the drawings, like reference numbers designate corresponding parts throughout the several views. [Brief description of the drawings]
[0047] [Figure 1] A method for coating microgels with proteins, antibodies, amino acids, biologics, or any protein-based material is shown that involves a series of fabrication steps. [Figures 2A-2E]FIG. 2A shows a surface-functionalized and protein-conjugated PAAm microgel. Type I collagen protein is conjugated onto the surface of the microgel. FIG. 2B shows a surface-functionalized and protein-conjugated PAAm microgel. A microgel with fluorescent antibodies conjugated onto the surface. FIG. 2C shows a surface-functionalized and protein-conjugated PAAm microgel. A fluorescent image showing attached cells binding to a collagen I-conjugated microgel. Cells were stained with phalloidin (green) for actin and Hoechst 33342 (blue) for nuclei. FIG. 2D shows a surface-functionalized and protein-conjugated PAAm microgel. A bright field microscope image showing the same cells adhering onto a collagen I-conjugated microgel. FIG. 2E shows a surface-functionalized and protein-conjugated PAAm microgel. Images on the right show surface-functionalized microgels with different proteins and antibodies. [Diagram 3] Shown are protein-conjugated polyacrylamide microgels for visualization of cell migration in the microgels. Top left are fluorescent images of a microgel with a type I collagen coating (green) on the surface to aid visualization during confocal microscopy, and a rhodamine B (red) polyacrylamide microgel. As an example, the time-lapse images (0-116 h) shown here show cells attaching and spreading over a 116 h culture on a collagen I-conjugated microgel, demonstrating biocompatibility and successful protein conjugation to the microgel particle surface. [Figure 4] Confocal images of live astrocytes binding to protein-conjugated microgel particles are shown. Cells were labeled with CellTracker™ Orange CMRA Dye (Cat. No. C34551) and imaged on a Nikon A1R HD25 confocal microscope using a high-resolution galvanometer scanner. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0048] Embodiments of the present disclosure provide microgels, microgel compositions, methods of making the microgels and microgel compositions, methods of using the microgels and microgel compositions, etc. Additional details are provided herein.
[0049] Before describing the present disclosure in more detail, it is to be understood that this disclosure is not limited to particular embodiments described, which can, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present disclosure will be limited only by the appended claims.
[0050] Where a range of values is provided, it is understood that (unless the context clearly dictates otherwise), to the tenth of the unit of the lower limit, each intervening value between the upper and lower limit of that range, and any other stated or intervening value in that stated range, is encompassed within the disclosure. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges, and are also encompassed within the disclosure, subject to any expressly excluded limitations in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the disclosure.
[0051] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of this disclosure, the preferred methods and materials are now described herein.
[0052] As will be apparent to those skilled in the art upon reading this disclosure, each of the individual embodiments described and illustrated herein has distinct components and features which may be readily separated from or combined with the features of any of the other several embodiments without departing from the scope or spirit of the disclosure. Any recited method may be carried out in the order of events recited or in any other order which is logically possible.
[0053] Embodiments of the present disclosure employ, unless otherwise indicated, techniques of chemistry, polymer chemistry, biochemistry, biology, and the like, which are within the skill of the art and which are fully explained in the literature.
[0054] The following examples are presented to provide those skilled in the art with a complete disclosure and description of the methods of carrying out the methods and the methods of using the compositions and compounds disclosed and claimed herein. Although efforts have been made to ensure accuracy with respect to numerical values (e.g., amounts, temperatures, etc.), some errors and deviations should be accounted for. Unless otherwise indicated, parts are parts by weight, temperature is in ° C, and pressure is atmospheric pressure. Standard temperature and pressure are defined as 25 ° C and 1 atmosphere.
[0055] Before embodiments of the present disclosure are described in detail, it will be understood that, unless otherwise indicated, the disclosure is not limited to particular materials, reagents, reactants, manufacturing processes, etc., as such may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting. It is also possible that steps can be carried out in differing order in the present disclosure, where this is logically possible.
[0056] It should be noted that as used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural references unless the context clearly dictates otherwise. Thus, for example, reference to a "support" includes a plurality of supports. In this specification and the following claims, reference will be made to a number of terms, which shall be defined to have the following meanings unless a contrary intention is apparent.
[0057] "Polymer" is understood to include, but is not limited to, homopolymers, copolymers, such as block, graft, random, and alternating copolymers, terpolymers, and the like, as well as blends and modifications thereof.
[0058] Embodiments of the present disclosure provide microgels (e.g., functionalized microgels), microgel compositions including a plurality of drug-functionalized microgel particles, methods of making the microgels and microgel compositions, methods of using the microgels and microgel compositions, and the like. In one embodiment, the present disclosure provides drug-functionalized microgel particles including one or more types of drugs bound to the microgel particles. In one aspect, the present disclosure is advantageous in that the microgel compositions can be produced quickly (e.g., within a few hours or within an hour), consuming minimal amounts of drugs, reducing costs. Also, the amount of drug(s) present on the drug-functionalized microgel particles can be precisely controlled. A plurality of drug-functionalized microgel particles can be used to study cell proliferation or degradation, cell responses to specific compounds, cell migration, differentiation, cell-cell interactions, and cell-extracellular matrix interactions.
[0059] The present disclosure provides a microgel polymer comprising a polymer functionalized with a first concentration of unquenched activated functional groups. The polymer can be polyethylene glycol, polyacrylic acid, polyacrylamide, hydroxyethyl methacrylate (HEMA), and copolymers thereof. The activated functional groups can be selected from activated esters (e.g., N-hydroxysuccinimide (NHS) ester groups, sulfonated NHS ester groups, fluorophenyl ester groups, tosylate ester groups, mesylate ester groups, O-acylisourea esters), N-acylbenzotriazole groups, anhydride groups, or activated carbonate functional groups (e.g., succinimidyl carbonate), as well as ketones / aldehydes for Schiff / imine chemistry, or maleimides / acrylates for click chemistry. The polymer can have a first concentration of activated functional groups of about 0.1-30 mol %, or about 1-30 mol %, or about 5-30 mol %. Generally, the microgel polymer can be prepared by mixing the monomers of interest to form the polymer and the activated functional groups, and the time to prepare the microgel polymer is about 20-30 minutes.
[0060] In addition, microgel polymers functionalized with unactivated functional groups (e.g., carboxylic acids) can be prepared, and the functional groups can be later activated via formation of activated esters (e.g., O-acylisourea esters or NHS esters), for example, using 1-ethyl-3-(-3-dimethylaminopropyl)carbodiimide hydrochloride.
[0061] The present disclosure also provides a microgel composition that can be made from a microgel polymer. The microgel composition includes a plurality of drug-functionalized microgel particles having a neutral charge. The drug-functionalized microgel particles can be made from a polymer (e.g., polyethylene glycol, polyacrylamide, HEMA, polyacrylic acid) that is functionalized with an activated functional group (e.g., an activated ester, an N-acylbenzotriazole group, an anhydride group, or an activated carbonate functional group), which is either quenched (e.g., reacted with an amine compound to prevent the activated functional group from hydrolysis) or is bound to at least one type of drug through the activated functional group. The polymer of the drug-functionalized microgel particles can have a concentration of activated functional groups (e.g., quenched plus drug-bound) of about 0.1-30 mol%, or about 1-30 mol%, or about 5-30 mol%.
[0062] In one embodiment, the drug-functionalized microgel particles have a longest dimension (e.g., diameter or width, length, or height) of about 5-150 μm and an aspect ratio of about 1-1.5, 1-1.2, or about 1. The drug-functionalized microgel particles can have a random three-dimensional shape (e.g., irregular shape). The drug-functionalized microgel particles can be divided into subgroups having dimensions as described herein. For example, the longest dimension (e.g., diameter or width, length, or height) can have subgroups ranging from about 5 micrometers to 200 micrometers, about 5 micrometers to 150 micrometers, about 5 micrometers to 100 micrometers, about 10 micrometers to 200 micrometers, about 10 micrometers to 150 micrometers, about 10 micrometers to 100 micrometers, about 10 micrometers, about 100 micrometers, about 150 micrometers, where the subgroups of drug-functionalized microgel particles can be selected based on the intended use, the cells of interest, the drug to be used, etc.
[0063] In one embodiment, the drug can be a biomolecule containing an amine group (e.g., a primary amine). For example, the drug can be a protein, and in particular, the drug can be an antibody, an enzyme, a cytokine, a growth factor, or an extracellular matrix component. In some embodiments, it is desirable for the drug-functionalized microgel particles to contain only one type of drug, while in other embodiments, it is desirable for the drug-functionalized microgel particles to contain two or more types of drugs (e.g., 2-10, or 2-5, or 2-3), such as two different types of antibodies, or an antibody and an enzyme, etc. In one aspect, about 90% or more, or about 95% or more of the at least one drug is present on the surface of the microgel particle. The amount of drug(s) on the drug-functionalized microgel particle can be precisely controlled during the fabrication of the drug-functionalized microgel particle by the amount of drug used in the fabrication method. In this way, drug-functionalized microgel particles can be made with a known amount of drug(s) and can be made in a cost-effective manner with little or no drug wastage. In this regard, about 10%-100%, about 25%-90%, and about 40%-80% of the activated functional groups are bound to the drug, respectively.
[0064] Having described the microgel polymers and microgel compositions, methods of making the microgel compositions are described below. In general, methods of making microgel compositions including drug-functionalized microgel particles can include forming a uniform distribution of microgel particles (described herein and in more detail below), the microgel particles including a polymer having activated functional groups. The uniform distribution of microgel particles can be separated using a centrifugation process to obtain a set of microgel particles, the set of microgel particles having a longest dimension of about 5-150 μm or about, an aspect ratio of about 1-1.5 and an aspect ratio of 1.2-1.3, or any subgroup thereof. The drug can be bound to a first amount of the activated functional groups of the set of microgel particles (e.g., about 10%-100%, about 25%-90%, about 40%-80% of the polymer), and a second amount (e.g., less than 10%, about 10%-75%, about 20%-60%) of the activated functional groups are not bound to the drug. The second set of amounts of drug functional groups can then be quenched with an amine (e.g., ethanolamine). Quenching can include mixing a molar excess of the amine relative to the second set of amounts of drug functional groups. Specifically, quenching can include mixing about 1.1-10, or about 1.1-3, or about 2 equivalents of an amine (e.g., a primary amine such as ethanolamine, hexylamine, butylamine, etc.) with the microgel particles immediately after reacting the drug with the activated functional groups. Typically, this process (e.g., separation, drug conjugation, and quenching) takes about 60-120 minutes.
[0065] Now, after generally describing the process, additional details are provided. In one embodiment, a method of making a composition of drug-functionalized microgel particles includes placing a microgel block (e.g., made from a microgel polymer described herein) on a first side of a mechanical sieve. For example, a syringe may be used to place the microgel block on the mechanical sieve. The mechanical sieve has a selective characteristic size sieve (e.g., about 5-150 micrometer mesh, about 65-85 micrometer mesh, about 74 micrometer mesh) such that particles having the desired dimensions are formed. The mechanical sieve has a second side opposite the first side, where the particles may be collected.
[0066] A first load (e.g., a uniformly distributed vertical load) may be applied to the microgel block to extrude the microgel block through the mechanical sieve to form a first plurality of fragments of the microgel block on a second side of the mechanical sieve. The first load may be provided by depression of a syringe to extrude the microgel block through the mesh of the sieve. The fragments of the microgel block may be received in a collection reservoir positioned adjacent to the second side of the mechanical sieve. Generally, this process may be repeated using the same mechanical sieve or using one or more other mechanical sieves having different mesh sizes to generate particles of desired dimensions. For example, a first plurality of fragments of the microgel block may optionally be placed (e.g., positioned, placed, etc.) on a first side of a mechanical sieve (e.g., the same sieve or another sieve of a different mesh size) and extruded by applying a second load (e.g., using a syringe) against the first plurality of fragments of the microgel block to extrude the fragments through the mechanical sieve to form a second plurality of fragments of the microgel block. The second plurality of fragments of the microgel block may be received in a collection reservoir. If desired, this process may be repeated until a uniform distribution (with a mean and standard deviation) of microgel particles is formed. The more times the process is repeated, the closer the normal distribution will be to the average particle size.
[0067] As described above, the uniform distribution of microgel particles can be separated using centrifugation, and then the drug(s) can be coupled to a portion of the activated functional groups while the remaining activated functional groups are quenched. This process (e.g., placement step(s), loading step(s), separation, coupling, quenching) should take about 60-120 minutes to complete. For example, the process of gel polymerization with functional activated esters (e.g., N-hydroxysuccinimide (NHS) ester groups) takes about 20-30 minutes, mechanical sieving to create gel particles takes about 5 minutes, separation to a specific particle size takes about 5 minutes, conjugation or coupling of the gel particles with protein drugs takes about 30 minutes, quenching with ethanol-amine takes about 30 minutes, and the total washing steps of the entire process take about 20 minutes.
[0068] The resulting microgel composition containing the drug-functionalized microgel particles has a neutral charge. EXAMPLES
[0069] Although the embodiments of the present disclosure have been described herein, the examples generally describe some additional embodiments. The embodiments of the present disclosure are described in conjunction with the examples and corresponding text and drawings, but there is no intention to limit the embodiments of the present disclosure to these descriptions. On the contrary, the intention is to cover all alternatives, modifications, and equivalents included within the spirit and scope of the embodiments of the present disclosure.
[0070] Example 1: Mechanical fabrication of microgel particles allows for the rapid generation of microgel particles with random and irregular shapes. Figure 1 shows that the method of coating microgels with proteins, antibodies, amino acids, biologics, or any protein-based material involves a series of fabrication steps.
[0071] 1) Polymerization of hydrogel materials containing crosslinking concentrations of, for example, NHS chemicals (N-hydroxy-succinimide).
[0072] 2) After polymerization, the hydrogel is milled by passing through a series of mechanical meshes or through the same mechanical mesh (not shown) until the final particle size distribution is produced. Typically, sieve sizes between 2 micrometers and 1 mm are used.
[0073] 3) After generation of the microgels, still containing the NHS or similar chemicals, a dilute mixture of the candidate proteinaceous material is added to the aqueous mixture and gently stirred to allow uniform attachment to the surface. Penetration of the material into the microgel depends on the concentration in solution, the time of coating, and the mesh size of the hydrogel material from which the microgel is made. The dilute solution results in surface coverage, as the surface is the first point of interaction and coverage is limited as the solution is depleted.
[0074] 4) The remaining NHS chemical is quenched, for example, using a high concentration of a small molecule (e.g., an amine) that will diffuse into the hydrogel, react with the NHS, and prevent it from hydrolyzing to acrylic acid.
[0075] 5) After generating the coated microgel ensemble and quenching the remaining NHS in the microgels, the microgel ensemble is sorted into a narrow size range for cell culture.
[0076] Figures 2A-1E show surface-functionalized and protein-conjugated PAAm microgels. Figure 3 shows protein-conjugated polyacrylamide microgels for visualizing cell migration in the microgels. Figure 4 shows confocal images of live astrocytes binding to protein-conjugated microgel particles. Additional details regarding the figures are provided in the figure captions.
[0077] Ratios, concentrations, amounts, and other numerical data may be expressed in range format. It is to be understood that such range format is used for convenience and brevity and should be interpreted flexibly to include not only the numerical values explicitly recited as the limits of the range, but also all individual numerical values or subranges subsumed within the range as if each numerical value and subrange were explicitly recited. To illustrate, a concentration range of "about 0.1% to about 5%" should be interpreted to include not only the explicitly recited concentrations of about 0.1% to about 5%, but also the individual concentrations (e.g., 1%, 2%, 3%, and 4%) and subranges within the indicated range (e.g., 0.5%, 1.1%, 2.2%, 3.3%, and 4.4%). In one embodiment, the term "about" may include conventional rounding to the nearest significant digit of the numerical value. In addition, the phrase "about 'x' to 'y'" includes "about 'x' to about 'y'".
[0078] Unless otherwise defined, all technical and scientific terms used have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Although any methods and materials similar or equivalent to those described can also be used in the practice or testing of this disclosure, the preferred methods and materials are now described herein.
[0079] The embodiments of the present disclosure employ, unless otherwise indicated, techniques of isolating, testing, and constructing materials that are within the skill of the art and are fully explained in the literature.
[0080] It should be emphasized that the above-described embodiments are merely examples of possible implementations. Many variations and modifications may be made to the above-described embodiments without departing from the principles of the present disclosure. All such modifications and variations are intended to be included herein within the scope of the present disclosure and protected by the following claims.
Claims
1. 1. A microgel composition comprising a plurality of drug-functionalized microgel particles having a neutral charge, the drug-functionalized microgel particles being made from a polymer, the polymer being quenched or functionalized with activated functional groups that are bonded to at least one type of drug via the activated functional groups, the drug-functionalized microgel particles having a longest dimension of about 5-150 μm and an aspect ratio of about 1-1.
5.
2. The microgel composition of claim 1, wherein the activated functional group is an activated ester, an N-acylbenzotriazole group, an anhydride group, or an activated carbonate functional group.
3. 3. The microgel composition of claim 2, wherein the activated ester is selected from an N-hydroxysuccinimide (NHS) ester group, a sulfonated NHS ester group, a fluorophenyl ester group, a tosylate ester group, a mesylate ester group, or an O-acylisourea.
4. The microgel composition of claim 2 , wherein the activated carbonate functional group is succinimidyl carbonate.
5. 2. The microgel composition of claim 1, wherein the drug-functionalized microgel particles have an aspect ratio of about 1.
6. The microgel composition of claim 1 , wherein the drug-functionalized microgel particles have a random three-dimensional shape.
7. 2. The microgel composition of claim 1, wherein the polymer is selected from polyethylene glycol, polyacrylamide, polyacrylic acid, HEMA, and combinations thereof.
8. 10. The microgel composition of claim 1, wherein the polymer prior to conjugation with the at least one type of drug has a concentration of activated ester groups of about 0.1-30 mol %.
9. 10. The microgel composition of claim 1, wherein about 90% or more of the at least one agent is present on the surface of the microgel particles.
10. 10. The microgel composition of claim 1, wherein greater than about 95% of the at least one drug is present on the surface of the drug-functionalized microgel particles.
11. The microgel composition of claim 1 , wherein the drug is a protein.
12. The microgel composition of claim 11 , wherein the protein is an antibody, an enzyme, or a cytokine.
13. The microgel composition of claim 1 , wherein the drug is a biomolecule containing an amine group.
14. The microgel composition of claim 1, wherein the drug-functionalized microgel particles comprise about 2 to 10 different types of drugs.
15. 1. A method of making a composition of drug-functionalized microgel particles, comprising: forming a uniform distribution of the microgel particles, the microgel particles comprising a polymer having activated functional groups; separating the uniform distribution of microgel particles using a centrifugation process to obtain a set of microgel particles, the set of microgel particles having a longest dimension of about 5-150 μm and an aspect ratio of about 1-1.5; binding a drug to a first amount of the activated functional groups of the polymer of the set of microgel particles, wherein a second amount of the activated functional groups is not bound to the drug; and c) quenching said second amount of set of drug functional groups with amine groups to form said drug-functionalized microgel particles.
16. 16. The method of claim 15, wherein the forming, separating, combining, and quenching steps are carried out for a period of about 60 to 120 minutes.
17. 17. The method of claim 15 or 16, wherein the drug-functionalized microgel particles have a neutral charge, the drug-functionalized microgel particles are made from a polymer, the polymer is quenched or functionalized with an activated functional group that is bonded to at least one type of drug via the activated functional group, and the drug-functionalized microgel particles have a longest dimension of about 5-150 μm and an aspect ratio of about 1-1.
5.
18. 18. The method of claim 17, wherein the activated functional group is an activated ester, an N-acylbenzotriazole group, an anhydride group, or an activated carbonate functional group.
19. 19. The method of claim 18, wherein the activated ester is selected from an N-hydroxysuccinimide (NHS) ester group, a sulfonated NHS ester group, a fluorophenyl ester group, a tosylate ester group, a mesylate ester group, or an O-acylisourea.
20. 20. The method of claim 18, wherein the activated carbonate functional group is succinimidyl carbonate.
21. The method of claim 15 , wherein the drug-functionalized microgel particles have an aspect ratio of about 1.
22. The method of claim 15 , wherein the drug-functionalized microgel particles have a random three-dimensional shape.
23. 16. The method of claim 15, wherein the polymer is selected from polyethylene glycol, polyacrylamide, polyacrylic acid, HEMA, and combinations thereof.
24. The method of claim 15, wherein the polymer prior to conjugation with the at least one type of drug has a concentration of activated ester groups of about 0.1 to 30 mole percent.
25. 16. The method of claim 15, wherein about 90% or more of the at least one agent is present on the surface of the microgel particles.
26. 16. The method of claim 15, wherein greater than about 95% of the at least one drug is present on the surface of the drug-functionalized microgel particles.
27. The method of claim 15 , wherein the agent is a protein.
28. 28. The method of claim 27, wherein the protein is an antibody, an enzyme, or a cytokine.
29. The method of claim 15 , wherein the agent is a biomolecule containing an amine group.
29. The method of claim 15, wherein the drug-functionalized microgel particles comprise about 2 to 10 different types of drugs.
30. 1. A method of making a composition of drug-functionalized microgel particles, comprising: disposing a microgel block on a first side of a mechanical sieve, the mechanical sieve having a selective characteristic size sieve, the mechanical sieve having a second side opposite the first side, the microgel block comprising a polymer having an activated functional group; applying a first load to the microgel block to extrude the microgel block through the mechanical sieve to form a first plurality of fragments of the microgel block on the second side of the mechanical sieve, wherein a collection reservoir is positioned adjacent the second side of the mechanical sieve to receive the fragments of the microgel block; Separating the uniform distribution of microgel particles using a centrifugation process using a new reservoir to obtain a set of microgel particles, the set of microgel particles having a longest dimension of about 5-150 μm and an aspect ratio of about 1-1.5; binding a drug to a first amount of the activated functional groups of the polymer of the set of microgel particles, wherein a second amount of the activated functional groups is not bound to the drug; and c) quenching the second amount of the drug functional groups with an amine group to form the composition of drug-functionalized microgel particles.
31. 31. The method of claim 30, wherein the steps of positioning the microgel block, applying the load, positioning the first plurality of pieces, separating, bonding, and quenching are carried out for a time period of about 60 to 120 minutes.
32. The method of claims 30 and 31, wherein quenching comprises using about 1.1 to 10 equivalents of the amine.
33. 33. The method of claim 32, wherein the amine is a primary amine.
34. 34. The method of claims 30 and 33, wherein quenching comprises using a molar excess of the amine relative to the second amount of set of drug functional groups.
35. The method of claims 30 and 33, wherein the load is a mechanical force.
36. 36. The method of claim 35, wherein the mechanical force is applied via a sterile syringe.
37. 36. The method of claim 35, wherein the mechanical sieve has a selective characteristic size sieve of about 65 to 85 micrometer mesh.
38. The method of any one of claims 30 to 37, wherein the first load is a uniformly distributed vertical load.
39. 31. The method of claim 30, wherein prior to the separating step, the method includes placing the first plurality of fragments of the microgel block on the first side of the mechanical sieve, applying a second load to the first plurality of fragments of the microgel block to push the fragments through the mechanical sieve to form a second plurality of fragments of the microgel block, collecting the second plurality of fragments of the microgel block in the collection reservoir, and repeating this step until a uniform distribution of the microgel particles is formed.
40. A microgel polymer comprising a polymer functionalized with a first concentration of unquenched activated functional groups.
41. 41. The microgel polymer of claim 40, wherein the activated functional group is an activated ester, an N-acylbenzotriazole group, an anhydride group, or an activated carbonate functional group.
42. 42. The microgel polymer of claim 41, wherein the activated ester is selected from an N-hydroxysuccinimide (NHS) ester group, a sulfonated NHS ester group, a fluorophenyl ester group, a tosylate ester group, a mesylate ester group, or an O-acylisourea.
43. 42. The microgel polymer of claim 41, wherein the activated carbonate functional group is succinimidyl carbonate.
44. 42. The microgel polymer of claim 41, wherein the first concentration of the activating functional groups is about 0.1-30 mol %.
45. 42. The microgel polymer of claim 41, wherein the first concentration of the activating functional groups is about 5-30 mole percent.
Citation Information
Patent Citations
Absorbing polyester copolymer having hydrogel-forming and autolytic properties and its use
JP2000026582A
Compositions and kits of pseudoplastic microgel matrices
JP2018511622A
Methods for Assembling Capture Particles
JP2020504177A
FasL-engineered biomaterials with immunomodulatory functions
JP2020511531A
